| Code | CSB-RA011586MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to briakinumab, targeting IL12A (interleukin-12 subunit alpha), also known as IL-12p35. IL12A encodes a critical subunit shared by both IL-12 and IL-23, two heterodimeric cytokines that play pivotal roles in regulating T-helper cell differentiation and inflammatory immune responses. IL-12 promotes Th1 cell development and interferon-gamma production, while IL-23 is essential for Th17 cell maintenance and function. Dysregulation of IL12A-containing cytokines has been implicated in various autoimmune and inflammatory conditions, including psoriasis, inflammatory bowel disease, and multiple sclerosis, making it an important therapeutic target.
Briakinumab was originally developed as a human monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23, showing promising efficacy in clinical trials for moderate-to-severe plaque psoriasis. This biosimilar antibody provides researchers with a valuable tool for investigating IL-12/IL-23 signaling pathways, studying immune-mediated inflammatory mechanisms, and exploring potential therapeutic interventions in autoimmune disease models.
There are currently no reviews for this product.